AIM: A systematic literature review and network meta-analysis of randomized controlled trials in HER2+ unresectable or metastatic breast cancer was conducted to compare progression-free survival (PFS) and overall survival (OS).
METHODS: Hazard ratios (HRs) and relative differences from fractional polynomials (FPs) for PFS and OS were assessed by Bayesian network meta-analyses.
RESULTS: For PFS, surface under the cumulative rankogram (SUCRA) ranked tucatinib combination highest in both HR and FP analyses, followed by T-DM1 monotherapy and neratinib plus capecitabine. For OS, SUCRA ranked tucatinib combination highest in both HR and FP analyses, followed by the pertuzumab combination and T-DM1, with similar scores.
CONCLUSION: Tucatinib combination and T-DM1 monotherapy consistently showed improved PFS and OS versus lapatinib/trastuzumab plus capecitabine and non-targeted treatments.
